Vitrakvi (Larotrectinib Sulfate) Patent Expiration, LOE Window & CMS Spending

Vitrakvi (Larotrectinib Sulfate) by Bayer: FDA Orange Book core substance LOE 2036-08-15 (last listed 2037-05-16), 0 AB generics, $61.8M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBayer
FDA Application & PathwayN210861 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2036-08-15
Last Listed Patent or Exclusivity Date2037-05-16
Orange Book Patents (*PED Extensions)15 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$61.8M
2024 Medicare Part D Spend$40.7M
2024 Medicaid Spend$21.2M
Reported Wholesale Price Change (CA SB 17)6 WAC filings (max 20.0% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bayer across sibling Meru public-data platforms.